Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform technology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2007-07-10. The company specializes in stabilizing carbohydrate molecules. The company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two advanced programs are the cosmetic skin lightener and diabetes drug. Other projects include the development of an anti-aging / cell protection library, a novel anti-wrinkle compound, and the launch of an anti-viral program. Its TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. The company is focused on three antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its subsidiary is TFChem S.A.R.L.
Follow-Up Questions
Who is the CEO of Sirona Biochem Corp?
Dr. Howard Y is the Chairman of the Board of Sirona Biochem Corp, joining the firm since 2020.
What is the price performance of SRBCF stock?
The current price of SRBCF is $0.0103, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Sirona Biochem Corp?
Sirona Biochem Corp belongs to Biotechnology industry and the sector is Health Care
What is Sirona Biochem Corp market cap?
Sirona Biochem Corp's current market cap is $0
Is Sirona Biochem Corp a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Sirona Biochem Corp, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell
